A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; Registrational
- Sponsors Novartis Pharmaceuticals
- 07 Mar 2017 Planned End Date changed from 1 Aug 2018 to 30 Apr 2018.
- 07 Mar 2017 Planned primary completion date changed from 1 Aug 2018 to 30 Apr 2018.
- 26 Feb 2017 This trial is completed in Slovakia.